Performance of HIV-1 Drug Resistance Testing at Low-Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naive Individuals

Background. Low-level viremia (LLV; human immunodeficiency virus [HIV-1] RNA 50–999 copies/mL) occurs frequently in patients receiving antiretroviral therapy (ART), but there are few or no data available demonstrating that HIV-1 drug resistance testing at a plasma viral load (pVL)

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2014-04, Vol.58 (8), p.1165-1173
Main Authors: Gonzalez-Serna, A., Min, J. E., Woods, C., Chan, D., Lima, V. D., Montaner, J. S. G., Harrigan, P. R., Swenson, L. C.
Format: Article
Language:English
Subjects:
Adult
AIDS
Antiretroviral drugs
Antiretrovirals
Biological and medical sciences
Clinical outcomes
Drug resistance
Drug Resistance, Viral
Drug therapy
Evolution, Molecular
Female
Genotype
Genotype & phenotype
Genotyping Techniques - methods
Health outcomes
HIV
HIV 1
HIV Infections - diagnosis
HIV Infections - virology
HIV-1 - drug effects
HIV-1 - genetics
HIV-1 - isolation & purification
HIV/AIDS
Human immunodeficiency virus
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Male
Medical sciences
Microbial Sensitivity Tests
Middle Aged
Patients
Polymerase chain reaction
Prognosis
Reproducibility of Results
RNA
Treatment Outcome
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Load
Viremia
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Low-level viremia (LLV; human immunodeficiency virus [HIV-1] RNA 50–999 copies/mL) occurs frequently in patients receiving antiretroviral therapy (ART), but there are few or no data available demonstrating that HIV-1 drug resistance testing at a plasma viral load (pVL)
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciu019